Objective: To test the hypothesis that chronic salbutamol intake improves performance during supramaximal exercise and to estimate the effects of this treatment on body composition, bone mass, and metabolic indices in healthy women. Methods: Fourteen female volunteers (seven sedentary and seven recreationally trained) performed a 30 second Wingate test with and without salbutamol ingestion (12 mg/day for four weeks) in a random, double blind, crossover design. Blood samples were collected at rest, at the end of the test, and during passive recovery for lactate measurement. Body composition and bone mass were determined by dual energy x ray absorptiometry. Results: Peak power appeared significantly earlier and was significantly (p,0.05) increased after salbutamol intake in all subjects. There was no difference in total work performed and fatigue indices with salbutamol compared with placebo. No significant alterations in lean or fat body mass and bone variables were observed with salbutamol treatment in either trained or untrained subjects during the trial. In contrast, blood lactate was significantly (p,0.05) increased during the recovery period after salbutamol ingestion compared with placebo. Conclusion: As in men, chronic administration of therapeutic concentrations of salbutamol did not induce an anabolic effect in women but increased maximal anaerobic power. Further studies are necessary to clarify the mechanisms involved.O nly a few studies have investigated the use of b 2 agonists as ergogenic aids during maximal or supramaximal exercise. This class of drug, in particular salbutamol, has become extensively used in the treatment of bronchial asthma and preterm labour. Moreover, b 2 agonists have received recent attention from the International Olympic Committee and the World Antidoping Agency as drugs for enhancing muscle mass. Indeed, whereas aerosol use of these drugs seems to have a relatively selective action on the receptors in bronchial muscle, anabolic properties have been demonstrated in several species after systemic use of some b 2 agonists coupled with a significant decrease in fat mass after relatively short periods of administration.1-3 In humans, both Martineau et al 4 and Caruso et al 5 6 found that short term therapeutic salbutamol administration improved strength but did not significantly affect lean body mass in healthy men. In agreement with these studies, we tested in a previous study 7 the effects of salbutamol (12 mg/day for three weeks) during a Wingate test in healthy male subjects and found a significant increase in peak power with salbutamol without any change in body composition. However, whether this drug increases performance or muscle mass in women has yet to be determined.A few studies on animals have also focused on the effects of b 2 agonists on bone mineral, with contradictory results. Indeed, both an increase 8 9 in suspended and denervated hindlimbs and a decrease under normal conditions 10-13 in bone density have been reported in animals after clenbuterol and salbutamol...